welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that target enrollment has been achieved for the company’s pivotal Phase 3 clinical trial, CPP FAP-310, evaluating CPP-1X/sulindac in adults with familial adenomatous polyposis (FAP).
expertly curated content related to this topic
-
Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at Hi...RATIONALE: Gathering medical and fam...
-
Cancer Chemoprevention: A Rapidly Evolving FieldCancer chemoprevention involves the chro...
-
A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy VolunteersA pharmacokinetic study in healthy volun...
-
PTSD common in patients with familial adenomatous polyposisPosttraumatic stress disorder is common ...
-
Evaluation of 28 Years of Surgical Treatment of Children and Young Adults with Familial Adenomatous PolyposisBACKGROUND : In this retrospective study...
-
Surgical Treatment of Familial Adenomatous Polyposis: Dilemmas and Current RecommendationsFamilial adenomatous polyposis (FAP) is ...
-
Endoscopic Management of Familial Adenomatous Polyposis in Patients Refusing ColectomyBACKGROUND AND STUDY AIMS : Colectomy pr...